- This topic has 0 replies, 1 voice, and was last updated 1 month ago by .
-
Posts
-
Hi all,
We are thrilled to share the newest program in the Additional Ventures suite of funding opportunities: The AV-CTIP Device Innovation Award.
We’d be so appreciative if you’d share this with any interested parties in your network. Always happy to discuss our programs with fellow HRA members and potential applicants!
All the best,
Kaitlin
Kaitlin Davis, PhD (she/her)
Director of Translational Sciences
Additional Ventures
http://www.additionalventures.org
_________________________________________________________
The AV-CTIP Device Innovation Award
Medical devices play a vital role in single ventricle care, but virtually no medical devices are specifically designed or engineered to meet the needs of single ventricle patients. To close this gap, Additional Ventures (AV), in partnership with the Consortium for Technology & Innovation in Pediatrics (CTIP), is launching the AV-CTIP Device Innovation Award. This initiative advances early-stage device concepts purpose-built for single ventricle patients across every stage of treatment. By supporting early-stage device innovators, this program seeks to fill critical gaps in care for single ventricle patients, catalyze clinical translation, and ultimately improve long term outcomes for this high-need community.
About the Partnership
This award combines Additional Ventures’ commitment to revolutionizing treatment and care for individuals with single ventricle heart disease with CTIP’s expertise in medical device development and commercialization. Together, we are providing the financial support, technical resources, and disease-specific expertise innovators need to move high-potential technologies from concept toward clinical impact.
Funding and Support
Awardees will be eligible for:
- Up to $1M in milestone-driven funding, up to approximately 3 years in total, with access to advising, services, and support throughout the award term.
- Tailored technical and business support through CTIP — including expert coaching, strategic connections, and access to consulting and service providers.
- Supplemental resources to advance projects through critical phases of device development, from early prototyping to clinical readiness.
What Fits
While surgical intervention has improved survival in single ventricle heart disease, patients still experience progressive complications. Few medical or device-based innovations address the unique physiological challenges or downstream complications of single ventricle heart disease.
We are particularly interested in technologies that can:
- Improve or augment the Fontan physiology, including support for low-pressure pulmonary flow, single-ventricle function, or optimized conduit/shunt performance
- Enable earlier intervention in failing Fontan patients or improve candidacy for transplantation
- Prevent, monitor, or treat sequelae such as lymphatic congestion, liver fibrosis, arrhythmias, or protein-losing enteropathy
- Support quality of life and daily function across pediatric and adult populations
- Deliver diagnostic or monitoring capabilities that provide actionable insights into Fontan performance and end-organ health
Who May Apply
Teams affiliated with U.S.-based academic institutions and companies are invited to apply. At minimum, teams must include a coordinating project lead, project manager, and appropriate clinical and technical expertise to support the success of their asset.
Applicants are welcome to include additional key personnel critical to the success of the project. These may include, but are not limited to:
- Co-investigators
- Clinical or technical collaborators
- Regulatory, reimbursement, or commercialization experts
- Consultants or contracted specialists in relevant areas (e.g., human factors, design controls, biostatistics)
All additional personnel should have a clearly defined role and level of effort. Letters of support or biosketches may be requested to document and assess their involvement.
Application Process
Applicants are encouraged to consult with program staff prior to submitting an LOI.
- Questions regarding scientific fit can be directed to Additional Ventures: [email protected].
- All other inquiries can be directed to CTIP: [email protected].
- Applicants may also bring questions to live information sessions with program staff, scheduled for September 24 and October 24, 2025, 10-11am PST, and hosted on Zoom.
- You must be logged in to reply to this topic.